Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: A systematic review

European Journal of Cancer Care

Volumn 22, Issue 6, 2013, Pages 714-725

  Chau, I ^a   Casciano, R ^b   Willet, J ^b   Wang, X ^c   Yao, J C ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b LA SER Analytica   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Health technology assessment; Neuroendocrine; Quality of life; Resource utilisation

Indexed keywords

ECONOMICS; HEALTH CARE COST; HEALTH SERVICE; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; NEUROENDOCRINE; NEUROENDOCRINE TUMOR; PATHOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESOURCE UTILISATION; REVIEW; UTILIZATION REVIEW;

HEALTH TECHNOLOGY ASSESSMENT; NEUROENDOCRINE; QUALITY OF LIFE; RESOURCE UTILISATION;

HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; NEUROENDOCRINE TUMORS; QUALITY OF LIFE;

EID: 84886949490     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12085     Document Type: Review

References (63)

1. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., De Haes J.C.J., Kaasa S., Klee M.C., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K.C.A., Sullivan M. & Takeda F. (1993) The European Organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85, 365-376.
2. Abu H.M., McPhail M.J., Zeidan B.A., Jones C.E., Johnson C.D. & Pearce N.W. (2009) Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours: is it worth it? Journal of the Pancreas 10, 276- 279.
3. Anthony L.B., Strosberg J.R., Klimstra D.S., Maples W.J., O'dorisio T.M., Warner R.R., Wiseman G.A., Benson A.B., III & Pommier R.F. (2010) The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated nets of the distal colon and rectum. Pancreas 39, 767-774.
4. Baudin E., Droz J.P., Paz-Ares L., Van Oosterom A.T., Cullell-Young M. & Schlumberger M. (2010) Phase ii study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. American Journal of Clinical Oncology 33, 83-88.
5. Beaumont J.L., Liu Z., Choi S., Yao J.C., Phan A.T. & Cella D. (2010) Relationship between neuroendocrine tumor-related symptoms and health-related quality of life. Presented at: 2010 Gastrointestinal Cancers Synmposium; 22-24 January 2010; Orlando, Florida.
6. Beaumont J.L., Cella D., Phan A.T., Choi S., Liu Z. & Yao J.C. (2012) Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41, 461-466.
7. Bilimoria K.Y., Bentrem D.J., Wayne J.D., Ko C.Y., Bennett C.L. & Talamonti M.S. (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Annals of Surgery 249, 63-71.
8. Boudreaux J.P., Klimstra D.S., Hassan M.M., Woltering E.A., Jensen R.T., Goldsmith S.J., Nutting C., Bushnell D.L., Caplin M.E. & Yao J.C. (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39, 753-766.
9. Castellano D., Capdevila J., Salazar R., Sastre J., Alonzo V., Llanos M., Garcia-Carbonero R., Abad A., Sevilla I. & Duran I. (2011) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendoendocrine tumor: a phase ii study of Spanish neuroendocrine tumor group (Getne0801). Journal of Clinical Oncology 29 (Suppl.), Abstract 4113.
10. Corleto V.D., Panzuto F., Falconi M., Cannizzaro R., Angeletti S., Moretti A., Delle F.G. & Farinati F. (2001) Digestive neuroendocrine tumours: diagnosis and treatment in Italy: a survey by the oncology study section of the Italian society of gastroenterology (SIGE). Digestive and Liver Disease 33, 217-221.
11. Davies A.H., Larsson G., Ardill J., Friend E., Jones L., Falconi M., Bettini R., Koller M., Sezer O., Fleissner C., Taal B., Blazeby J.M. & Ramage J.K. (2006) Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer 42, 477-484.
12. Davies A.H.G., King B., Jervis N., Larsson G., Ardill J. & Ramage J.K. (2003) Differences in the perception of quality of life issues between healthcare workers and patients with metastatic carcinoid or neuroendocrine tumours [Abstract]. Endocrine Related Cancer 10 (Suppl.), 509.
13. Dimitroulopoulos D., Xynopoulos D., Tsamakidis K., Paraskevas E., Zisimopoulos A., Andriotis E., Fotopoulou E., Kontis M. & Paraskevas I. (2004) Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World Journal of Gastroenterology 10, 3628-3633.
14. Dixon E. & Pasieka J.L. (2007) Functioning and nonfunctioning neuroendocrine tumors of the pancreas. Current Opinion in Oncology 19, 30-35.
15. Eriksson B., Kloppel G., Krenning E., Ahlman H., Plockinger U., Wiedenmann B., Arnold R., Auernhammer C., Korner M., Rindi G. & Wildi S. (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8-19.
16. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P. & Raymond E. (2006) Safety, pharmacokinetic, and antitumor activity of Su11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology 24, 25-35.
17. Fernandez-Cruz L., Herrera M., Saenz A., Pantoja J.P., Astudillo E. & Sierra M. (2001) Laparoscopic pancreatic surgery in patients with neuroendocrine tumours: indications and limits. Best Practice and Research Clinical Endocrinology and Metabolism 15, 161-175.
18. Frojd C., Larsson G., Lampic C. & Von Essen L. (2007) Health related quality of life and psychosocial function among patients with carcinoid tumours: a longitudinal, prospective, and comparative study. Health Quality of Life Outcomes 5, 18.
19. Frojd C., Lampic C., Larsson G. & Von Essen L. (2009) Is satisfaction with doctors' care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report. Scandinavian Journal of Caring Sciences 23, 107-116.
20. Grover A.C., Libutti S.K., Pingpank J.F., Helsabeck C., Beresnev T. & Alexander H.R., Jr (2004) Isolated Hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136, 1176-1182.
21. Halfdanarson T.R., Rabe K.G., Rubin J. & Petersen G.M. (2008) Pancreatic neuroendocrine tumors (PNETS): incidence, prognosis and recent trend toward improved survival. Annals of Oncology 19, 1727-1733.
22. Haugland T., Vatn M.H., Veenstra M., Wahl A.K. & Natvig G.K. (2009) Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Quality of Life Research 18, 719-726.
23. Hauso O., Gustafsson B.I., Kidd M., Waldum H.L., Drozdov I., Chan A.K. & Modlin I.M. (2008) Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113, 2655-2664.
24. Hobday T.J., Rubin J., Holen K., Picus J., Donehower R.C., Marschke R., Maples W., Lloyd R., Mahoney M. & Erlichman C. (2007) Mco44h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. Journal of Clinical Oncology 25, S4504.
25. Jaroszewski D.E., Schlinkert R.T., Thompson G.B. & Schlinkert D.K. (2004) Laparoscopic localization and resection of insulinomas. Archives of Surgery 139, 270-274.
26. Jensen R.T., Berna M.J., Bingham D.B. & Norton J.A. (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113, 1807-1843.
27. Johnson M.A., Rajendran S., Balachandar T.G., Kannan D.G., Jeswanth S., Ravichandran P. & Surendran R. (2006) Central pancreatectomy for benign pancreatic pathology/trauma: is it a reasonable pancreas-preserving conservative surgical strategy alternative to standard major pancreatic resection? Australian and New Zealand Journal of Surgery 76, 987-995.
28. Kaltsas G.A., Besser G.M. & Grossman A.B. (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 25, 458-511.
29. Kang H., O'Connell J.B., Leonardi M.J., Maggard M.A., McGory M.L. & Ko C.Y. (2007) Rare tumors of the colon and rectum: a national review. International Journal of Colorectal Disease 22, 183-189.
30. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V. & Suster S. (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39, 707-712.
31. Korse C.M., Bonfrer J.M., Aaronson N.K., Hart A.A. & Taal B.G. (2009) Chromogranin a as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 89, 296-301.
32. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M. & Fuchs C.S. (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 26, 3403-3410.
33. Kulke M.H., Siu L.L., Tepper J.E., Fisher G., Jaffe D., Haller D.G., Ellis L.M., Benedetti J.K., Bergsland E.K., Hobday T.J., Van Cutsem E., Pingpank J., Oberg K., Cohen S.J., Posner M.C. & Yao J.C. (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. Journal of Clinical Oncology 29, 934-943.
34. Larsson G., Sjoden P.O., Oberg K., Eriksson B. & Von Essen L. (2001) Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica 40, 825-831.
35. Larsson G., Hagluund K. & Von Essen L. (2003) Distress, quality of life and strategies to 'keep a good mood' in patients with carcinoid tumours: patient and staff perceptions. European Journal of Cancer Care 12, 46-57.
36. Larsson G., Von Essen L. & Sjoden P.O. (2007) Are importance-satisfaction discrepancies with regard to ratings of specific health-related quality-of-life aspects valid indicators of disease- and treatment-related distress among patients with endocrine gastrointestinal tumours? European Journal of Cancer Care 16, 493-499.
37. Liu H., Peng C., Zhang S., Wu Y., Fang H., Sheng H. & Peng S. (2007) Strategy for the surgical management of insulinomas: analysis of 52 cases. Digestive Surgery 24, 463-470.
38. Major P., Figueredo A., Tandan V., Bramwell V., Charette M. & Oliver T. (2003) The role of octreotide in the management of patients with cancer. Current Oncology 10, 161-179.
39. Maroun J., Kocha W., Kvols L., Bjarnason G., Chen E., Germond C., Hanna S., Poitras P., Rayson D., Reid R., Rivera J., Roy A., Shah A., Sideris L., Siu L. & Wong R. (2006) Guidelines for the diagnosis and management of carcinoid tumours, 1: the gastrointestinal tract. a statement from a Canadian National Carcinoid Expert Group. Current Oncology 13, 1-10.
40. Mazzaglia P.J., Berber E., Milas M. & Siperstein A.E. (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142, 10-19.
41. Moher D., Liberati A., Tetzlaff J. & Altman D.G. (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Annals of Internal Medicine 151, 264-269, W64.
42. Muros M.A., Varsavsky M., Iglesias-Rozas P., Valdivia J., Delgado Y.R., Forrer F., Bodei L. & Paganelli G. (2009) Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clinical Translations in Oncology 11, 48-53.
43. Murphy G., Perras C., Desjardins B., Chen S., Moulton K., Jonker D., Perlman K., Pasieka J., Ezzat S., Cripps C., Mensinskai S. & Skidmore B. (2008) Octreotide for endocrine, oncologic and gastrointestinal disorders: systematic review and budget impact analysis. Technical Report Number 111. Ottawa: Canadian Agency For Drugs And Technologies In Health.
44. Norton J.A., Kivlen M., Li M., Schneider D., Chuter T. & Jensen R.T. (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Archives of Surgery 138, 859-866.
45. O'Toole D., Ducreux M., Bommelaer G., Wemeau J.L., Bouche O., Catus F., Blumberg J. & Ruszniewski P. (2000) Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88, 770-776.
46. Oberg K., Akerstrom G., Rindi G. & Jelic S. (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 (Suppl. 5), V223-V227.
47. Ong S.L., Garcea G., Pollard C.A., Furness P.N., Steward W.P., Rajesh A., Spencer L., Lloyd D.M., Berry D.P. & Dennison A.R. (2009) A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology 9, 583-600.
48. 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136, 1218-1226.
49. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Winkler R.E., Klimovsky J., Lebwol D. & Jehl V. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2): a randomised, placebo-controlled, phase 3 study. Lancet 378, 2005-2012.
50. Pezzilli R., Campana D., Morselli-Labate A.M., Fabbri M.C., Brocchi E. & Tomassetti P. (2009) Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. World Journal of Gastroenterology 15, 5067-5073.
51. Ramage J.K. & Davies A.H. (2003) Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocrine Related-Cancer 10, 483-486.
52. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Horsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R. & Ruszniewski P. (2011a) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal Medicine 364, 501-513.
53. Raymond E., Hobday T., Castellano D., Reidy-Lagunes D., Garcia-Carbonero R. & Carrato A. (2011b) Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Reviews 30 (Suppl. 1), 19-26.
54. Rinke A., Muller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T. & Arnold R. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the Promid Study Group. Journal of Clinical Oncology 27, 4656-4663.
55. Schonfeld W.H., Eiken E.P., Woltering E.A., Modlin I.M., Anthony L., Villa K.F. & Zaggari M. (1998) The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and vipoma. International Journal of Technology Assessment in Health Care 14, 514-525.
56. Teh S.H., Deveney C. & Sheppard B.C. (2007) Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? American Journal of Surgery 193 (5 SPEC. ISS.), 610-613.
57. Teunissen J.J., Kwekkeboom D.J. & Krenning E.P. (2004) Quality of life in patients with gastroenteropancreatic tumors treated with 177lu-Dota0, Tyr3octreotate. Journal of Clinical Oncology 22, 2724-2729.
58. Vinik E., Carlton C.A., Silva M.P. & Vinik A.I. (2009) Development of the norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas 38, E87-E95.
59. Vinik E., Silva M.P. & Vinik A.I. (2011) Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40, 97-109.
60. Yao J.C. (2007) Neuroendocrine tumors: molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice and Research Clinical Endocrinology and Metabolism 21, 163-172.
61. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A. & Evans D.B. (2008) One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. Journal of Clinical Oncology 26, 3063-3072.
62. Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O'dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A. & Wiedenmann B. (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28, 69-76.
63. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., De Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D. & Oberg K. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal Medicine 364, 514-523.